This approval enhances Alembic Pharma’s portfolio, which now totals 216 ANDAs from the USFDA, including 188 final and 28 ...

Alembic Pharmaceuticals said that it has received final approval from the US Food & Drug Administration (US FDA) for its abbreviated new drug application (ANDA) Alcaftadine Ophthalmic Solution.

Aldeyra Therapeutics has resubmitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for topical ...

On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...

Eli Lilly will invest $4.5 billion to create the Lilly Medicine Foundry, which the drug giant says will be the first-ever ...

ALT5 Sigma Corporation (NASDAQ:ALTS) (”ALT5” or the “Company”), a fintech innovator providing next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, ...

Researchers at the RIKEN Cluster for Pioneering Research (CPR) have developed technology that can alter, within the body, the ...

Ward County will continue to pursue a grant for a program to address opioid use disorder among jail inmates, despite one ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

The FDA received an application for Nubeqa as a potential treatment option with androgen deprivation therapy for metastatic ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments ...